R&D | March 26, 2026
Zealand Pharma launches major US research hub in Cambridge, Massachusetts
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Capital infusion to accelerate Earendil’s R&D platform
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The kit features ViaPlex 405 Barcoding Dye for the 405 nm laser/Pacific Blue filter and ViaPlex 488 Barcoding Dye for the 488 nm laser/FITC filter
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Subscribe To Our Newsletter & Stay Updated
